What is SK pharmteco?
SK pharmteco operates as a key portfolio company under SK Inc., a prominent South Korean conglomerate, strategically bolstering SK's pharmaceutical division. The company's facility in Dublin, Ireland, known as Swords Campus, boasts nearly six decades of experience in manufacturing Active Pharmaceutical Ingredients (APIs) and intermediates. For over thirty years, this campus has been a leader in the development, scale-up, and commercial production of highly potent chemical intermediates and APIs. SK biotek Ireland is equipped to handle multi-scale production, from grams to hundreds of kilograms, managing materials with an Occupational Exposure Limit (OEL) as low as 10 ng/m³. This integrated site combines manufacturing, R&D, and quality control laboratories, emphasizing a strong safety compliance policy and adherence to high-quality standards, establishing a proven track record as a reliable supplier of HPAPIs to a diverse clientele.
How much funding has SK pharmteco raised?
SK pharmteco has raised a total of $164M across 1 funding round:
Unspecified
$164M
Unspecified (2024): $164M, investors not publicly disclosed
What's next for SK pharmteco?
The recent major strategic investment signals a new phase of growth and development for SK pharmteco. This substantial backing is expected to fuel further advancements in its highly potent API manufacturing capabilities and potentially expand its R&D initiatives. The company's established expertise in handling complex chemical intermediates and APIs, coupled with its robust safety and quality protocols, positions it for continued leadership in the pharmaceutical supply chain. Future endeavors will likely focus on leveraging this capital to enhance its technological infrastructure, broaden its service offerings, and solidify its market position as a critical partner for pharmaceutical companies worldwide.
See full SK pharmteco company page
